Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial
- Categories: Medications, Metabolic Health, Weight Loss/Management
- Tags Metabolic Syndrome
Type Article
Journal Article
Authors
C. W. Le Roux; M. Davies; J. P. Frias; P. N. Laursen; I. Lingvay; S. Machineni; A. Varbo; J. P. Wilding; S. O. Wallenstein; L. Perreault
Year of publication
2021
Publication/Journal
Obesity facts
Volume
14
Issue
Pages
52‐
Abstract
Introduction: In the STEP 1 trial, semaglutide 2.4 mg once weekly and placebo (PBO) were associated with body weight reductions of 14.9% and 2.4%, respectively (estimated treatment difference: 12.4%; p